)
Yael Weiss, MD, PhD
CEO and Founder
Mahzi Therapeutics
Yael Weiss founded Mahzi Therapeutics to develop therapies for ultra-rare genetic neurodevelopmental disorders. Mahzi partners directly with patient foundations — supporting their path toward drug development and bringing programs in-house once pre-clinical proof of concept is established.
Yael earned her MD from Hadassah Medical School at the Hebrew University in Jerusalem and her PhD from the Weizmann Institute of Science in Rehovot, Israel. She brings more than 25 years of industry experience spanning medical, clinical, and business development roles.
She began her career at Genzyme where she worked in rare disease drug development. She then joined Merck, where she progressed from Medical Director to Director of Global Scientific Affairs and Executive Director of Regional Deals. She subsequently held a senior role at Ultragenyx Pharmaceutical before founding Mahzi.
Yael is a 2022 Termeer Fellow and a member of the American Society of Gene and Cell Therapy (ASGCT), the American Epilepsy Society (AES) Translational Committee, and the N=1 Collaborative. She serves as a board member or advisor to the FOXG1 Research Foundation, KCNT1 Epilepsy Foundation and ZTTK SON-Shine Foundation and an advisor to SparkNS.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}